{"prompt": "['Clinical Study Protocol', 'R2810-ONC-1676 Amendment 7', 'Table 7:', 'Dose Reductions for Pemetrexed: Hematologic Toxicity', 'Toxicity', 'Dose Modification', 'Nadir ANC <500/mm\u00b3 and nadir platelets >50,000/mm\u00b3', '75% of previous dose', 'Nadir platelets <50,000/mm\u00b3 without bleeding regardless of', '75% of previous dose', 'nadir ANC', 'Nadir platelets <50,000/mm\u00b3 with bleeding regardless of nadir', '50% of previous dose', 'ANC', 'If patients develop nonhematologic toxicity >grade 3, treatment should be held until resolution to', \"less than or equal to the patient's pretherapy value. Treatment should be resumed according to the\", 'guidelines in Table 8.', 'Table 8:', 'Dose Reductions for Pemetrexed: Nonhematologic Toxicity', 'Toxicity', 'Dose Modification', 'Any grade 3a or 4 toxicities except mucositis', '75% of previous dose', 'Any diarrhea requiring hospitalization (regardless of grade) or', '75% of previous dose', 'grade 3 or 4 diarrhea', 'Grade 3 or 4 mucositis', '50% of previous dose', 'a', 'Excluding grade 3 transaminase elevation, for which no dose modification is required', 'Pemetrexed therapy should be discontinued if patient experiences any hematologic or', 'nonhematologic grade 3 or 4 toxicity (except transaminase elevations) after 2 dose reductions, and', 'immediately for grade 3 or 4 neurologic toxicity at any time.', 'Renally impaired patients: In clinical studies, patients with creatinine clearance >45 mL/min', 'required no dose adjustments other than those required for all patients. Insufficient numbers of', 'patients with creatinine clearance <45 mL/min have been treated to make dosage recommendations', 'for this group. Therefore, pemetrexed should not be administered to patients with creatinine', 'clearance <45 mL/min using the standard Cockcroft and Gault formula. Caution should be used', 'in administering pemetrexed concurrently with nonsteroidal anti-inflammatory drugs to patients', 'with creatinine clearance <80 mL/min.', 'Cockcroft and Gault Formula:', 'Creatinine Clearance, Males (mL/min) =', '[140 - Age in years] * [Actual Body Weight in kg]/', '72', '* [Serum Creatinine, mg/dL]', 'Creatinine Clearance, Females (mL/min) = estimate creatinine clearance for males * 0.85', '8.4.2.', 'Topotecan Dose Modifications', 'The dose reduction guidelines for topotecan are in Table 9.', 'Regeneron Pharmaceuticals, Inc.', 'Page 77 of 145', 'CONFIDENTIAL', 'VV-RIM-00146791-1.0 Approved - 14 Apr 2021 GMT-5:00']['Clinical Study Protocol', 'R2810-ONC-1676 Amendment 7', 'Table 9:', 'Dose Reductions for Topotecan', 'Toxicity', 'Dose Modification', 'ANC <1000/mm\u00b3 or', 'Delay next cycle of topotecan until hematologic', 'Platelet count of <100,000/mm\u00b3 or', 'or renal recovery. No dose reduction unless', 'criteria below are met.', 'Hemoglobin <9.0 g/dL or', 'Serum creatinine >1.5 mg/dL', 'ANC <500/mm\u00b3 in preceding cycle', 'Permanently reduce topotecan dose to 0.75 mg/m\u00b2', 'or administer prophylactic granulocyte colony-', 'stimulating factor during subsequent cycles', 'Platelets <25,000/mm\u00b3 in preceding cycle', 'Permanently reduce topotecan dose to 0.75 mg/m\u00b2', 'Creatinine clearance 20 mL/min to 39 mL/min in', 'Permanently reduce topotecan dose to 0.75 mg/m\u00b2', 'preceding cycle', 'Special safety considerations for topotecan:', 'Topotecan-induced neutropenia can lead to neutropenic colitis, which can be fatal. In', 'patients presenting with neutropenia, fever, and a compatible pattern of abdominal', 'pain, consider the possibility of neutropenic colitis.', 'For patients for whom dose was increased to 1.25 mg/m\u00b2 after the first course and', 'then experienced any toxicity requiring dose reduction, the recommended first dose', 'reduction is to 1.0 mg/m\u00b2.', 'Topotecan can cause interstitial lung disease (ILD), which can be fatal. Monitor', 'patients for symptoms indicative of interstitial lung disease (cough, fever, dyspnea,', 'or/or hypoxia), and discontinue topotecan if a new diagnosis of ILD is confirmed.', '8.4.3.', 'Irinotecan Dose Modifications', 'The starting dose for irinotecan is 100 mg/m\u00b2 weekly X 4, followed by 10 to 14 days of rest.', 'Patients who experience toxicity at 100 mg/m\u00b2 will undergo a first dose reduction (dose level -1)', 'to 75 mg/m\u00b2. Patients who experience toxicity at 75 mg/m\u00b2 will undergo a second dose reduction', 'to dose level -2) of 50 mg/m\u00b2.', 'For patients who experience toxicity with 125 mg/m\u00b2 after an increase from the starting dose of', '100 mg/m\u00b2 (described in Section 8.1.2.3), the recommended first dose reduction is to 100 mg/m\u00b2', 'A new cycle of therapy should not begin until the granulocyte count has recovered to >1500/mm\u00b3,', 'and the platelet count has recovered to >100,000/mm\u00b3, and treatment-related diarrhea has fully', 'resolved. Treatment should be delayed for 1 to 2 weeks to allow for recovery of irinotecan-related', 'toxicities. If the patient has not recovered after a 2-week delay, consideration should be given to', 'discontinuing irinotecan. Dose modifications of irinotecan for specific toxicities are provided in', 'Table 10.', 'Regeneron Pharmaceuticals, Inc.', 'Page 78 of 145', 'CONFIDENTIAL', 'VV-RIM-00146791-1.0 Approved - 14 Apr 2021 GMT-5:00']\n\n###\n\n", "completion": "END"}